Published in Vaccine on March 01, 2011
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis (2012) 1.00
Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clin Vaccine Immunol (2011) 0.81
Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients. Med Microbiol Immunol (2012) 0.81
H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses. PLoS One (2012) 0.79
Naturally-acquired influenza-specific CD4+ T-cell proliferative responses are impaired in HIV-infected African adults. PLoS One (2012) 0.79
Antibody persistence after Pandemic H1N1 2009 influenza vaccination among healthcare workers in Pune, India. Hum Vaccin Immunother (2012) 0.78
Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine. PLoS One (2012) 0.77
Vaccination in HIV-infected adults. AIDS Patient Care STDS (2014) 0.77
Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand. Clin Infect Dis (2015) 0.75
Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine. Infect Ecol Epidemiol (2013) 0.75
Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals. Hum Vaccin Immunother (2015) 0.75
Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial. Expert Rev Vaccines (2016) 0.75
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I. Infect Dis Ther (2017) 0.75
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol (1999) 11.94
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA (2009) 10.13
The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) (1972) 7.42
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med (2009) 5.73
Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med (2009) 5.46
A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med (2009) 4.20
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet (2009) 3.98
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (2009) 3.97
Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA (2009) 3.32
Immunity to influenza in man. Annu Rev Microbiol (1983) 3.22
Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis (2009) 3.12
Immunogenicity and protective efficacy of influenza vaccination. Virus Res (2004) 2.65
Influenza-associated morbidity and mortality in young and middle-aged women. JAMA (1999) 2.08
Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (2010) 2.03
Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med (2001) 2.03
Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS (2010) 1.87
Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis (1999) 1.75
Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med (2008) 1.72
Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis (2008) 1.57
Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis (2010) 1.52
Influenza in patients with human immunodeficiency virus infection. Chest (1990) 1.50
Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis (1983) 1.46
A Hong Kong influenza immunity three years after immunization. JAMA (1973) 1.40
Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI). Euro Surveill (2009) 1.39
Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis (2011) 1.33
The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA (1989) 1.32
Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS (1998) 1.24
Initial identification and characterization of an emerging zoonotic influenza virus prior to pandemic spread. J Clin Microbiol (2010) 1.23
Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 1.22
Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine (2000) 1.22
Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1999) 1.16
Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J (2008) 1.15
Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine (2009) 1.11
A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity. J Hyg (Lond) (1983) 1.06
Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS (2010) 1.04
Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol (2007) 1.03
Persistence of influenza A/New Jersey/76 (Hsw1N1) antibody one year after vaccination. Dev Biol Stand (1978) 0.96
Antibody decline in children following A/New Jersey/76 influenza virus immunization. J Pediatr (1980) 0.93
The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis (1996) 0.88
Development of a multiplex real-time RT-PCR assay for detection of influenza A, influenza B, RSV and typing of the 2009-H1N1 influenza virus. J Virol Methods (2010) 0.88
Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS (2010) 0.85
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med (2006) 5.14
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS (2009) 4.02
Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis (2009) 3.48
Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis (2002) 3.27
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20
Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis (2011) 2.86
Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. J Clin Microbiol (2010) 2.79
Arboviral etiologies of acute febrile illnesses in Western South America, 2000-2007. PLoS Negl Trop Dis (2010) 2.60
Feasibility and acceptability of rapid HIV testing in jail. AIDS Patient Care STDS (2007) 2.52
Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007. Clin Infect Dis (2009) 2.50
Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis (2007) 2.29
Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog (2008) 2.23
Sex differences in learning in chimpanzees. Nature (2004) 2.22
Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis (2010) 2.17
Evidence for subclinical avian influenza virus infections among rural Thai villagers. Clin Infect Dis (2011) 2.13
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis (2010) 2.03
Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health (2005) 2.02
Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J Infect Dis (2007) 1.95
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One (2010) 1.86
Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS (2010) 1.80
Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study. J Trauma (2011) 1.77
Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One (2010) 1.75
Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr (2009) 1.70
Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis (2009) 1.70
Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS (2008) 1.69
Depressive symptoms and mortality in men: results from the Multiple Risk Factor Intervention Trial. Stroke (2004) 1.68
Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr (2008) 1.66
Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm (2011) 1.64
Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther (2010) 1.63
Multiplex PCR to diagnose bloodstream infections in patients admitted from the emergency department with sepsis. J Clin Microbiol (2009) 1.63
Provider factors associated with intramedullary nail use for intertrochanteric hip fractures. J Bone Joint Surg Am (2010) 1.62
Strategies to improve access to sterile syringes for injection drug users. AIDS Read (2002) 1.62
Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial. Infect Control Hosp Epidemiol (2010) 1.60
Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine (2011) 1.59
Invasive mold infections following combat-related injuries. Clin Infect Dis (2012) 1.55
Associations of smoking prevalence with individual and area level social cohesion. J Epidemiol Community Health (2004) 1.53
ZIP-code-based versus tract-based income measures as long-term risk-adjusted mortality predictors. Am J Epidemiol (2006) 1.53
Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis (2010) 1.52
Etiology of acute undifferentiated febrile illness in the Amazon basin of Ecuador. Am J Trop Med Hyg (2009) 1.52
Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J Infect Dis (2011) 1.51
Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J Infect Dis (2013) 1.50
Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Am J Trop Med Hyg (2006) 1.49
Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant (2002) 1.48
Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays. Bioinformatics (2012) 1.46
Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis (2002) 1.46
Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? J Acquir Immune Defic Syndr (2010) 1.46
Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J Neurochem (2013) 1.43
Meningococcal disease in US military personnel before and after adoption of conjugate vaccine. Emerg Infect Dis (2015) 1.40
Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS (2010) 1.39
Body size and predatory performance in wolves: is bigger better? J Anim Ecol (2009) 1.36
Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol (2011) 1.35
Infectious etiologies of acute febrile illness among patients seeking health care in south-central Cambodia. Am J Trop Med Hyg (2012) 1.34
Differential effects of dengue virus on infected and bystander dendritic cells. J Virol (2005) 1.33
Spatial dimensions of dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999-2003). PLoS Negl Trop Dis (2012) 1.32
Human brain glycogen metabolism during and after hypoglycemia. Diabetes (2009) 1.32
Influenza virus infection among pediatric patients reporting diarrhea and influenza-like illness. BMC Infect Dis (2010) 1.30
Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord (2010) 1.30
Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS. PLoS One (2011) 1.29
Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol (2002) 1.26
A three-component biomarker panel for prediction of dengue hemorrhagic fever. Am J Trop Med Hyg (2012) 1.23
Initial identification and characterization of an emerging zoonotic influenza virus prior to pandemic spread. J Clin Microbiol (2010) 1.23
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol (2003) 1.23
Four dengue virus serotypes found circulating during an outbreak of dengue fever and dengue haemorrhagic fever in Jakarta, Indonesia, during 2004. Trans R Soc Trop Med Hyg (2006) 1.20
Genomic signature-based identification of influenza A viruses using RT-PCR/electro-spray ionization mass spectrometry (ESI-MS) technology. PLoS One (2010) 1.20
Comparison of two active surveillance programs for the detection of clinical dengue cases in Iquitos, Peru. Am J Trop Med Hyg (2009) 1.20
Evaluation of an influenza-like illness case definition in the diagnosis of influenza among patients with acute febrile illness in Cambodia. BMC Infect Dis (2010) 1.20
Personal, indoor, and outdoor VOC exposures in a probability sample of children. J Expo Anal Environ Epidemiol (2004) 1.19
Identification of a novel human papillomavirus by metagenomic analysis of samples from patients with febrile respiratory illness. PLoS One (2013) 1.19
CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis (2010) 1.18
Phylogenetic analysis of a novel molecular isolate of spotted fever group Rickettsiae from northern Peru: Candidatus Rickettsia andeanae. Ann N Y Acad Sci (2005) 1.18
Discovery proteomics and nonparametric modeling pipeline in the development of a candidate biomarker panel for dengue hemorrhagic fever. Clin Transl Sci (2012) 1.17
Dengue virus infections in a cohort of schoolchildren from Maracay, Venezuela: a 2-year prospective study. Vector Borne Zoonotic Dis (2008) 1.16
Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med (2004) 1.15
Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation (2002) 1.14
Obesity among HIV-infected persons: impact of weight on CD4 cell count. AIDS (2010) 1.14
Molecular epidemiology of Plasmodium falciparum resistance to antimalarial drugs in Indonesia. Am J Trop Med Hyg (2005) 1.13
HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One (2013) 1.13
Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology (2009) 1.12
Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci (2010) 1.12
Ninety-day mortality after intertrochanteric hip fracture: does provider volume matter? J Bone Joint Surg Am (2010) 1.12